{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:18:49Z","timestamp":1790205529329,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["2011616035"],"award-info":[{"award-number":["2011616035"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.tiv.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T19:46:07Z","timestamp":1481139967000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp\/CYP3A4 interplay in the human intestine ex vivo"],"prefix":"10.1016","volume":"40","author":[{"given":"Ming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge A.M.","family":"de Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evita","family":"van de Steeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina H.","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geny M.M.","family":"Groothuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2016.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1023\/A:1012155124489","article-title":"Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond","volume":"14","author":"Artursson","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tiv.2016.12.002_bb0010","series-title":"Models for Assessing Drug Absorption and Metabolism","first-page":"239","article-title":"Brain microvessel endothelial cell culture systems","author":"Audus","year":"1996"},{"key":"10.1016\/j.tiv.2016.12.002_bb0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/mp900253n","article-title":"The drug transporter-metabolism alliance: uncovering and defining the interplay","volume":"6","author":"Benet","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tiv.2016.12.002_bb0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1556\/APhysiol.99.2012.002","article-title":"Investigation of drug metabolism in various segments of small intestine in the rat","volume":"100","author":"Bojcsev","year":"2013","journal-title":"Acta Physiol. Hung."},{"key":"10.1016\/j.tiv.2016.12.002_bb0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejps.2014.09.007","article-title":"Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling","volume":"65","author":"Bosgra","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2016.12.002_bb0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-007-0447-5","article-title":"Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil","volume":"64","author":"Choi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tiv.2016.12.002_bb0035","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1124\/jpet.300.3.1036","article-title":"Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4","volume":"300","author":"Cummins","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.102.044719","article-title":"In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model","volume":"305","author":"Cummins","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0045","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/nprot.2010.111","article-title":"Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies","volume":"5","author":"de Graaf","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tiv.2016.12.002_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"DeGorter","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tiv.2016.12.002_bb0055","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1021\/mp500330y","article-title":"Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine","volume":"11","author":"Drozdzik","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tiv.2016.12.002_bb0060","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/dmd.112.049965","article-title":"P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism","volume":"41","author":"Dufek","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJM199801013380107","article-title":"Quinidine","volume":"338","author":"Grace","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tiv.2016.12.002_bb0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-3565(24)35293-0","article-title":"Influence of P-glycoprotein on the transport and metabolism of Indinavir in Caco-2 cells expressing cytochrome P-450 3A4","volume":"292","author":"Hochman","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0075","series-title":"Optimization in Drug Discovery","first-page":"19","article-title":"Use of Caco-2 cell monolayers to study drug absorption and metabolism","author":"Hu","year":"2004"},{"key":"10.1016\/j.tiv.2016.12.002_bb0080","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/jps.21756","article-title":"N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a \u201cchemical knock-out equivalent\u201d to assess the impact of efflux transporters on oral drug absorption in the rat","volume":"98","author":"Kalgutkar","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2016.12.002_bb0085","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-008-9532-4","article-title":"Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC\/MS\/MS method combined with novel in-silico peptide selection criteria","volume":"25","author":"Kamiie","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tiv.2016.12.002_bb0090","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejps.2005.11.011","article-title":"Development, validation and utility of an in vitro technique for assessment of potential clinical drug\u2013drug interactions involving P-glycoprotein","volume":"27","author":"Keogh","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2016.12.002_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tiv.2010.09.011","article-title":"The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices","volume":"25","author":"Khan","year":"2011","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2016.12.002_bb0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.tiv.2015.04.011","article-title":"Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors ex vivo","volume":"29","author":"Li","year":"2015","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2016.12.002_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.2047","article-title":"P-gp activity and inhibition in the different regions of human intestine ex vivo","author":"Li","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/dmd.115.068684","article-title":"The consequence of drug-drug interactions influencing the interplay between P-gp and Cyp3a: an ex vivo study with rat precision-cut intestinal slices","volume":"44","author":"Li","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0115","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/dmd.108.020859","article-title":"Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats","volume":"36","author":"MacLean","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0120","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/dmd.105.009035","article-title":"Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine","volume":"34","author":"Martignoni","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0125","doi-asserted-by":"crossref","first-page":"38617","DOI":"10.1074\/jbc.M505974200","article-title":"Why is quinidine an inhibitor of cytochrome P450 2D6?: the role of key active-site residues in quinidine binding","volume":"280","author":"McLaughlin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tiv.2016.12.002_bb0130","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.107.019687","article-title":"Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats","volume":"36","author":"Mitschke","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)38103-0","article-title":"In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes","volume":"289","author":"Nielsen","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0140","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1021\/mp900258z","article-title":"Interplay of transporters and enzymes in drug and metabolite processing","volume":"6","author":"Pang","year":"2009","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tiv.2016.12.002_bb0145","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/jps.20664","article-title":"Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A","volume":"95","author":"Peng","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2016.12.002_bb0150","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2174\/1389200216666150401110610","article-title":"Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition","volume":"15","author":"Shi","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tiv.2016.12.002_bb0155","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s00228-008-0512-8","article-title":"Dual drug interactions via P-glycoprotein (P-gp)\/cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil","volume":"64","author":"Srinivas","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tiv.2016.12.002_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2005.06.005","article-title":"Expression and function of efflux drug transporters in the intestine","volume":"109","author":"Takano","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"The International Transporter Consortium","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tiv.2016.12.002_bb0170","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1124\/dmd.105.005686","article-title":"Characterization of rat small intestinal and colon precision-cut slices as an in vitro system for drug metabolism and induction studies","volume":"33","author":"van de Kerkhof","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0175","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1124\/dmd.106.011148","article-title":"Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations","volume":"34","author":"van de Kerkhof","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0180","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.112.049023","article-title":"Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1","volume":"41","author":"van de Steeg","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.12.002_bb0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tiv.2016.12.002_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.tiv.2016.12.002_bb0195","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.tiv.2016.12.002_bb0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0169-409X(97)00041-0","article-title":"The barrier function of CYP3A4 and P-glycoprotein in the small bowel","volume":"27","author":"Watkins","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tiv.2016.12.002_bb0205","article-title":"The roles of membrane transporters on the oral drug absorption","volume":"1","author":"Zhen","year":"2013","journal-title":"J. Mol. Pharm. Org. Process Res."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316302533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316302533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:13:03Z","timestamp":1749802383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233316302533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":41,"alternative-id":["S0887233316302533"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2016.12.002","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp\/CYP3A4 interplay in the human intestine ex vivo","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}